Key Highlights

  • 4DMEDICAL shares gained 3.80% to AUD 3.55 in the latest market snapshot.
  • CT:VQ is expanding the company’s functional lung imaging platform.
  • 4DMEDICAL has added commercial and strategic partnerships in 2026.
  • The company continues to expand beyond its original U.S. market.

4DMEDICAL Ltd (ASX:4DX) gained 3.80% to AUD 3.55, keeping one of the market’s standout healthcare technology stocks in focus after a 361.04% one-year gain in the supplied data. The company is continuing to expand its advanced respiratory imaging platform, with CT:VQ approvals, customer adoption, international expansion and new technology partnerships shaping the latest phase of its growth story.

What Does 4DMEDICAL Do?

4DMEDICAL is a medical technology company focused on advanced diagnostic imaging for respiratory conditions. Its platform uses proprietary functional lung imaging technologies to provide quantitative information that can complement conventional anatomical imaging. The company’s technology portfolio is aimed at helping clinicians assess lung function and respiratory disease.

Why Functional Lung Imaging Matters

Respiratory diseases can involve changes in both lung structure and function. Conventional imaging can show anatomy, while functional imaging can provide additional information about how air and blood move through the lungs. The healthcare technology opportunity therefore sits within a broader shift toward more quantitative, software-enabled diagnostic tools.

CT:VQ Broadens the Product Platform

CT:VQ is a non-contrast CT-based ventilation-perfusion imaging solution. During 2026, the technology received regulatory progress in multiple markets, including TGA approval in Australia and CE Mark certification for commercial use in the European Union. These milestones expand the potential addressable market while adding new commercial deployment opportunities.

Partnerships Extend the Ecosystem

In August, 4DMEDICAL announced an OEM and reseller Partnership with Azra AI to connect lung findings with coordinated care. The company also entered a distribution agreement and strategic Investment partnership with RevealDx, combining its functional imaging capabilities with AI-based pulmonary nodule assessment. These arrangements broaden the platform beyond a standalone imaging product.

Growth After a Major Share-Price Run

The 3.80% gain comes against a 361.04% one-year rise in the supplied market data. That performance makes execution particularly important. Investors are likely to monitor commercial adoption, customer conversion, reimbursement, international launches and the financial contribution from the company’s expanding technology portfolio.

Key Risks for 4DX Investors

Healthcare technology businesses face regulatory, reimbursement, adoption and integration risks. Hospitals can take time to implement new diagnostic technologies, while customer budgets and clinical workflows influence uptake. The company also faces execution risk as it expands geographically and adds products and partnerships.

What Could Come Next for 4DMEDICAL?

The next stage centres on turning regulatory access and partnerships into recurring commercial adoption. CT:VQ deployment, international expansion and integration of complementary technologies will remain important indicators as the company builds out its respiratory imaging ecosystem. The company must also demonstrate that new products and acquisitions can be integrated without disrupting customer delivery or increasing costs faster than commercial revenue. International expansion adds further execution complexity because regulatory, reimbursement and healthcare procurement environments differ between markets.